Vineet Laboratories Limited (VINEETLAB) Fair Value & Analysis
Basic Materials · IN · Market cap ₹646M
Fair value as of: Jul 3, 2026
From 9 valuation models · updated today
Share price −2.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹29.01 – ₹47.87 · fair‑value band ₹20.50 – ₹55.64 · the ₹33.65 price screens below the ₹38.07 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vineet Laboratories Limited (VINEETLAB) currently trades at ₹33.65, while our model-based Fair Value estimate is ₹38.07 — implying the stock looks roughly 13.1% undervalued today. We read business quality at 47/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Vineet Laboratories Limited generated revenue of ₹560M at a net margin of -18.1%. Revenue declined 13.4% year over year. It earns a return on equity of -74.2%. Net debt stands at ₹394M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vineet Laboratories Limited reported revenue of ₹750M in FY2025 versus ₹2.4B in FY2021, a compound −25.5%/yr. Reported net income was −₹202M in FY2025.
Is VINEETLAB fairly valued? → Check now
Similar stocks
6 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | €448.00 | €191.66 | -57% |
| Shin-Etsu Chemical Co SHECY | $22.77 | $13.22 | -42% |
| BASF SE BAS | €50.82 | €9.45 | -81% |
| Ningxia Baofeng Energy Group 600989 | ¥21.72 | ¥42.42 | +95% |
| Dow Inc D1OW34 | R$43.91 | R$31.57 | -28% |
| Ganfeng Lithium Group 002460 | ¥65.65 | ¥18.75 | -71% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Vineet Laboratories Limited (VINEETLAB) undervalued?
What is the fair value of VINEETLAB?
What is the quality score of VINEETLAB?
What is the revenue of Vineet Laboratories Limited (VINEETLAB)?
What is the net profit margin of VINEETLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.